賽生藥業
Central Plaza
22nd Floor 381 Middle Huaihai Road
Shanghai
China
86 21 2319 3800
https://www.sciclone.com
版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 860
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Hong Zhao | CEO, President & Executive Director | 8.59M | 無 | 1963 |
| Mr. Chihwen Shao | VP & Head of Technical Operations and Pharmacovigilance | 無 | 無 | 1963 |
| Mr. Min Jia | VP & Head of Immunization Business Unit | 無 | 無 | 1971 |
| Mr. Yansong Chang | VP & GM of Oncology Business Unit | 無 | 無 | 1969 |
| Mr. Mingxiang Wu | VP and Head of Market Access & Commercial Operation (MACO) Department | 無 | 無 | 1967 |
| Dr. Xiaoning Guo | VP, Head of Research & Development Department and Chief Medical Officer | 無 | 無 | 1978 |
| Mr. Lianzong Wu | VP and Head of Registration & Pharmaceutical Affairs Department | 無 | 無 | 1976 |
| Dr. Li Mao M.D. | VP, GM of Research and Development & Chief Medical Officer | 無 | 無 | 1957 |
| Dr. Min Wu | VP & Chief Business Development Officer | 無 | 無 | 無 |
| Ms. Rongrong Pan | Company Secretary | 無 | 無 | 1979 |
描述
SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company's proprietary product is Zadaxin, which is used for the treatment of chronic hepatitis B. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma. The company's pipeline products comprise Vibativ for the treatment of hospital-acquired and ventilator associated bacterial pneumonia; Omburtamab for the treatment of CNS/leptomeningeal metastasis from neuroblastoma; RRx-001, a small molecule immunotherapeutic, which treats solid tumors; PEN-866, a drug conjugate for solid tumors; HSP90-PI3K SMDC for the treatment of solid tumors; PT-112 for the treatment of late stage prostate cancer and cholangiocarcinoma; and ABTL-0812 for the treatment of endometrial/lung/pancreatic cancer. The company sells its proprietary, in-licensed, and promotion products through distributors to hospitals and pharmacies. SciClone Pharmaceuticals (Holdings) Limited was founded in 1990 and is headquartered in Shanghai, the People's Republic of China.
公司管治
截至 無 止，賽生藥業 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
